ScripVenture capital funding for biopharmaceutical companies overall may be down in 2023, but that does not mean that investors have stopped placing big bets on the industry. Three companies announced rece
ScripThe frenzied flow of funds into biopharma venture capital has resulted in a lot of big bets, but recent small financings are encouraging as cash is harder to come by at the earliest stages of drug dis
Medtech InsightWhile the traditional summer recess led to an expected drop in the number of alliances in August, there was still a good level of activity from medtech players – with a couple of joint ventures thrown